Key facts
- Viva Vision Biotech’s last known valuation is $256.6M (Nov 2025).
- It has raised $107.4M; the latest was IPO in Feb 2026.
- Notable investors include HSG (Hong Kong), Guangdong Technology Financial Group, Lapam Capital, V-Capital, Shenzhen GTJA Investment Group — 26 tracked in total.
- Status: In IPO Registration.
- ·The complete investor list — 26 names
- ·Watchlist + deal alerts for Viva Vision Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Viva Vision Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Viva Vision Biotech
Developer and manufacturer of innovative ophthalmology therapeutics and ophthalmic formulations designed for anterior and posterior segment eye diseases. The company provides clinical-stage drug candidates and a robust R&D pipeline, enabling patients and healthcare systems with novel treatment options, improved efficacy, and solutions for unmet ocular medical needs.
- Sector
- Healthcare
- HQ
- Wenzhou, China
- Founded
- 2016
- Employees
- 63
- Website
- vivavisionbio.com/
- Ownership
- In IPO Registration
Viva Vision Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Viva Vision Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Viva Vision Biotech in its N-PORT filings yet. We sweep new filings monthly.